P63085 (MK01_MOUSE) Mus musculus (Mouse)
Mitogen-activated protein kinase 1 UniProtKBInterProSTRINGInteractive Modelling
358 aa; Sequence (Fasta) ;
6 identical sequences: Rattus norvegicus: P63086, A6JSN9; Mus spicilegus: A0A8C6HGX0; Mus caroli: A0A6P5R8X8; Mesocricetus auratus: A0A1U7QEZ9; Cricetulus griseus: A0A8C2QMB3
It is possible new templates exist for this target since these models were created.
Available Structures
60 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal structure of a designed selected Ankyrin Repeat protein in complex with the phosphorylated … |
Heteromer P63086; | 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of Erk2 complex with KIM peptide derived from MKP3 |
Heteromer P63086; Q64346; | |||||
| Assess | ||||||
| Crystal structure of rat ERK2 complexed with docking peptide from ISG20 |
Heteromer P63086; Q96AZ6; | 1×ANP; | ||||
| Assess | ||||||
| Crystal structure of ERK2/DCC peptide complex |
Heteromer P63086; Q63155; | 2×SCN; | ||||
| Assess | ||||||
| Docking motif interactions in the MAP kinase ERK2 |
Heteromer P35236; P63086; | |||||
| Assess | ||||||
| Crystal structure of a designed selected Ankyrin Repeat protein in complex with the MAP kinase ERK2 |
Heteromer P63086; | |||||
| Assess | ||||||
| COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52 | monomer | 1×MG; 1×ATP; | ||||
| Assess | ||||||
| Structure of ERK2 (SPE) mutant (S246E) | monomer | |||||
| Assess | ||||||
| PHOSPHORYLATED MAP KINASE ERK2 | monomer | |||||
| Assess | ||||||
| Crystal structure of mitogen-activated protein kinase 1 wtERK2 at 1.45A | monomer | |||||
| Assess | ||||||
| ERK2 R65S mutant complexed with AMP-PNP | monomer | 1×ANP; 1×SO4; 1×MG; | ||||
| Assess | ||||||
| ERK2 intrinsically active mutant (I84A) | monomer | |||||
| Assess | ||||||
| Crystal structure of ERK2 AMP-PNP complex | monomer | 1×ANP; 1×SO4; 1×MG; | ||||
| Assess | ||||||
| ERK2 Intrinsically active mutant R65S | monomer | |||||
| Assess | ||||||
| ERK2 MAP kinase with mutations at Helix-G | monomer | |||||
| Assess | ||||||
| STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE | monomer | 1×SO4; | ||||
| Assess | ||||||
| ERK2 (I84A) in complex with AMP-PNP | monomer | 1×SO4; 1×ANP; 1×MG; | ||||
| Assess | ||||||
| Rat ERK2 E320K | monomer | |||||
| Assess | ||||||
| THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025 | monomer | 1×SB4; | ||||
| Assess | ||||||
| THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE | monomer | 1×SO4; 1×OLO; | ||||
| Assess | ||||||
| A Double Mutant Rat Erk2 in Complex With a Pyrazolo[3,4-d]pyrimidine Inhibitor | monomer | 1×2H1; | ||||
| Assess | ||||||
| Crystal Structure of ERK-2 with hypothemycin covalently bound | monomer | 1×HMY; | ||||
| Assess | ||||||
| Rat ERK2 D319N | monomer | 1×SO4; | ||||
| Assess | ||||||
| ATP-bound form of the ERK2 kinase | monomer | 3×GOL; 1×ATP; 2×MG; 1×PEG; | ||||
| Assess | ||||||
| Monoclinic crystal form of the apo-ERK2 | monomer | 6×GOL; 1×SO4; 1×PGE; | ||||
| Assess | ||||||
| Crystal Structure of a Double Mutant Rat Erk2 Complexed With a Type II Quinazoline Inhibitor | monomer | 1×G17; | ||||
| Assess | ||||||
| Dissecting Therapeutic Resistance to ERK Inhibition Rat Wild Type SCH772984 in complex with (3R)-1-… | monomer | 1×38Z; 3×SO4; 1×PG4; 2×DMS; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an inhibitor | monomer | 1×SO4; 2×DMS; 1×42A; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an inhibitor | monomer | 1×Z8B; 11×DMS; 2×SO4; 1×BME; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 1×SO4; 1×DF8; 1×DMS; | ||||
| Assess | ||||||
| Dissecting Therapeutic Resistance to ERK Inhibition Rat Mutant SCH772984 in complex with (3R)-1-(2-… | monomer | 1×38Z; 5×SO4; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an inhibitor | monomer | 1×DX4; 1×SO4; 11×DMS; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 1×SO4; 1×AOC; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an inhibitor | monomer | 1×620; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 1×SO4; 1×DQ2; 1×DMS; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an inhibitor | monomer | 1×6PB; 10×DMS; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 3×DMS; 1×SO4; 1×DJ2; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 3×DMS; 1×SO4; 1×E9W; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 4×DMS; 2×SO4; 1×ZAS; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 5×DMS; 2×SO4; 1×E3K; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 2×SO4; 1×E2K; 3×DMS; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 4×DMS; 1×SO4; 1×DU8; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an inhibitor | monomer | 1×620; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an inhibitor | monomer | 1×TT4; 2×DMS; 2×SO4; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an inhibitor | monomer | 1×TT4; 1×SO4; | ||||
| Assess | ||||||
| ADP-bound form of the ERK2 kinase | monomer | 1×ADP; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 1×SO4; 1×DKW; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 2×SO4; 1×DTW; 4×DMS; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 1×DVZ; 2×DMS; 1×SO4; | ||||
| Assess | ||||||
| Phosphorylated ERK2 with Vertex-11e | monomer | 1×390; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an adenosine derivative | monomer | 4×DMS; 1×SO4; 1×A3N; | ||||
| Assess | ||||||
| Crystal structure of ERK2 in complex with an inhibitor | monomer | 1×DX4; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure at room temperature of Erk2 in complex with an inhibitor | monomer | 1×SO4; 1×42A; | ||||
| Assess | ||||||
| ERK2 MAP kinase with the activation loop of p38alpha | monomer | |||||
| Assess | ||||||
| Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Ki… | monomer | 1×3G7; 3×SO4; | ||||
| Assess | ||||||
| Discovery of 1-1H-Pyrazolo 4,3-c pyridine-6-yl urea Inhibitors of Extracellular Signal Regulated Ki… | monomer | 1×6S9; 5×SO4; | ||||
| Assess | ||||||
| Discovery of MLi-2, an Orally Available and Selective LRRK2 Inhibitor that Reduces Brain Kinase Act… | monomer | 1×81Y; 4×SO4; | ||||
| Assess | ||||||
| Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology | monomer | 2×SO4; 1×F8V; | ||||
| Assess | ||||||
| Unphosphorylated Mitogen Activated Protein Kinase ERK2 in Complex with (4-{[5-Carbamoyl-4-(3-Methyl… | monomer | 1×SO4; 1×S91; 3×BME; | ||||
| Assess | ||||||
| Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology | monomer | 2×SO4; 1×G67; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4gt3.1.A | monomer | 0.89 | 1×ATP; | 100.00 | ||
| Assess | ||||||